Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sichuan Clover Biopharmaceuticals Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner, CHEN, STACY BROWN, within 1 distinct art unit. CHEN, STACY BROWN is the busiest examiner, accounting for 1 busiest examiner pending action.
With 1 pending office action total, the company's active docket is centralized. The use of 1 distinct examiner and 1 distinct art unit suggests that all current prosecution is subject to a single set of departmental standards. This 1 busiest examiner pending action is the only active response requirement for the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009714 | VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | CHEN, STACY BROWN | 49d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009714 | VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | CHEN, STACY BROWN | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18009714 | VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | CHEN, STACY BROWN | 1672 | §103§112 | Non-Final OA | 49d overdue | Pending | Dec 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSichuan Clover Biopharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Stacy Brown Chen has the most, with 1 of Sichuan Clover Biopharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.